VeriStrat validated in patients with non-small-cell lung cancer
Mené sur 142 patients atteints d'un cancer du poumon non à petites cellules de stade IIIB ou IV traité en seconde ligne par erlotinib ou chimiothérapie, cet essai de phase III évalue la valeur d'un test protéomique pour prédire, en termes de survie globale, le bénéfice associé au traitement
In the decade since the first report that a mutation in EGFR correlated with response to gefitinib, 1 new treatment regimens for patients with advanced stage non-small-cell lung cancer have slowly emerged. Molecular analysis of tumour specimens is recommended to guide treatment decisions for these patients by both the American Society of Clinical Oncology 2 and the European Society of Medical Oncology. 3 Patients with tumours with an activating EGFR mutation should receive an EGFR tyrosine-kinase inhibito ...
The Lancet Oncology , commentaire, 2013